skip to main content

'Insanity Virus' Research Advances

The first human trials are underway to test whether antibody therapy can treat schizophrenia and multiple sclerosis.

| 1 min read
Follow on GoogleGoogle News Preferred Source
Placeholder image

Newsletter

Sign up for our email newsletter for the latest science news

Sign Up

In 2010, Discover reported on a theory that brain diseases such as multiple sclerosis (MS) and schizophrenia might have a common source — a virus. ("The Insanity Virus," June 2010) Researchers found mounting evidence that we carry this virus in our DNA, like the genes for left-handedness. What’s more, infections such as influenza, picked up from our environment early in life, might be the trigger for these diseases.

Placeholder image showing Earth from space with an alert icon and the message ‘This image is no longer available.’

June 2010 issue

The theory: Millions of years ago, an ancient human ancestor contracted a retrovirus that inserted its DNA into the host’s reproductive germ cells, passing the viral DNA down the ancestral line. The virus, called human endogenous retrovirus W (HERV-W), codes for a protein that, when activated, sets off an inflammatory cascade in the brain that leads to symptoms. This theory is gaining traction among psychiatrists, especially as a potential explanation for schizophrenia, a disease once considered a result of bad parenting.

Since 2010, clinical trials have tried to target and neutralize that HERV-W-coded protein using monoclonal antibody therapy (MAT). Monoclonal antibodies are engineered to target specific receptors on infected cells, like inserting a key into a lock. Once the antibody binds, the immune system sees the cell as foreign and launches an attack.

In 2012, this approach passed FDA Phase I (human) trials as an MS treatment. Because of MAT’s proven safety, HERV-W expert Hervé Perron, scientific director of GeNeuro in Switzerland, is looking to start Phase II trials for patients with schizophrenia. But Perron is emphatic: Although the research looks promising, especially for use in MS, a lot still needs to be done until we can see this as a general treatment for schizophrenia or MS.

Meet the Author

Published In

Stay Curious

JoinOur List

Sign up for our weekly science updates

View our Privacy Policy

SubscribeTo The Magazine

Save up to 40% off the cover price when you subscribe to Discover magazine.

Subscribe